Vogelbaum M - Search Results

1

Glioblastomas induce T-lymphocyte death by two distinct pathways involving gangliosides and CD70.

Chahlavi A, Rayman P, Richmond AL, Biswas K, Zhang R, Vogelbaum M, Tannenbaum C, Barnett G, Finke JH. Chahlavi A, et al. Among authors: vogelbaum m. Cancer Res. 2005 Jun 15;65(12):5428-38. doi: 10.1158/0008-5472.CAN-04-4395. Cancer Res. 2005. PMID: 15958592

2

IL-13R(alpha)2, a decoy receptor for IL-13 acts as an inhibitor of IL-4-dependent signal transduction in glioblastoma cells.

Rahaman SO, Sharma P, Harbor PC, Aman MJ, Vogelbaum MA, Haque SJ. Rahaman SO, et al. Among authors: vogelbaum ma. Cancer Res. 2002 Feb 15;62(4):1103-9. Cancer Res. 2002. PMID: 11861389

3

Cyclooxygenase-2 (COX-2) expression by immunohistochemistry in glioblastoma multiforme.

Prayson RA, Castilla EA, Vogelbaum MA, Barnett GH. Prayson RA, et al. Ann Diagn Pathol. 2002 Jun;6(3):148-53. doi: 10.1053/adpa.2002.33900. Ann Diagn Pathol. 2002. PMID: 12089724

4

Intracranial navigation by using low-field intraoperative magnetic resonance imaging: preliminary experience.

Kanner AA, Vogelbaum MA, Mayberg MR, Weisenberger JP, Barnett GH. Kanner AA, et al. J Neurosurg. 2002 Nov;97(5):1115-24. doi: 10.3171/jns.2002.97.5.1115. J Neurosurg. 2002. PMID: 12450034

5

Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells.

Rahaman SO, Harbor PC, Chernova O, Barnett GH, Vogelbaum MA, Haque SJ. Rahaman SO, et al. Oncogene. 2002 Dec 5;21(55):8404-13. doi: 10.1038/sj.onc.1206047. Oncogene. 2002. PMID: 12466961

6

Serum transthyretin monomer as a possible marker of blood-to-CSF barrier disruption.

Marchi N, Fazio V, Cucullo L, Kight K, Masaryk T, Barnett G, Vogelbaum M, Kinter M, Rasmussen P, Mayberg MR, Janigro D. Marchi N, et al. Among authors: vogelbaum m. J Neurosci. 2003 Mar 1;23(5):1949-55. doi: 10.1523/JNEUROSCI.23-05-01949.2003. J Neurosci. 2003. PMID: 12629200 Free PMC article. Clinical Trial.

7

Serum S100beta: a noninvasive marker of blood-brain barrier function and brain lesions.

Kanner AA, Marchi N, Fazio V, Mayberg MR, Koltz MT, Siomin V, Stevens GH, Masaryk T, Aumayr B, Vogelbaum MA, Barnett GH, Janigro D. Kanner AA, et al. Cancer. 2003 Jun 1;97(11):2806-13. doi: 10.1002/cncr.11409. Cancer. 2003. PMID: 12767094 Free PMC article.

8

Cyclooxygenase-2 in oligodendroglial neoplasms.

Castilla EA, Prayson RA, Kanner AA, Rybicki LA, Tubbs RR, Vogelbaum MA, Barnett GH. Castilla EA, et al. Cancer. 2003 Oct 1;98(7):1465-72. doi: 10.1002/cncr.11632. Cancer. 2003. PMID: 14508834 Free article.

9

Posterior fossa metastases: aggressive treatment improves survival.

Kanner AA, Suh JH, Siomin VE, Lee SY, Barnett GH, Vogelbaum MA. Kanner AA, et al. Stereotact Funct Neurosurg. 2003;81(1-4):18-23. doi: 10.1159/000075099. Stereotact Funct Neurosurg. 2003. PMID: 14742959

10

Posterior fossa metastases: risk of leptomeningeal disease when treated with stereotactic radiosurgery compared to surgery.

Siomin VE, Vogelbaum MA, Kanner AA, Lee SY, Suh JH, Barnett GH. Siomin VE, et al. J Neurooncol. 2004 Mar-Apr;67(1-2):115-21. doi: 10.1023/b:neon.0000021785.00660.2b. J Neurooncol. 2004. PMID: 15072456

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

309 results

Search Page